Download PDF
Thromb Haemost 2005; 94(04): 780-786
DOI: 10.1160/TH05-02-0082
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1

Evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin
Simone Rost
1   Institute of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany
,
Andreas Fregin
1   Institute of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany
,
Mirja Hünerberg
1   Institute of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany
,
Carville G. Bevans
2   Department of Structural Biology, Max Planck Institute of Biophysics, Frankfurt/Main, Germany
,
Clemens R. Müller
1   Institute of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany
,
Johannes Oldenburg
1   Institute of Human Genetics, University of Würzburg, Biocenter, Würzburg, Germany
3   Institute of Transfusion Medicine and Immunohaematolgy, DRK Blood Donor Service Baden-Württemberg-Hessen, Frankfurt/M, Germany
4   Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany
› Author AffiliationsGrant support:The study was supported by grants from the DFG (01-100/3), the National Genome Research Net Cardiovascular Diseases (BMBF-DLR-01GS 0424) and Baxter to J.O.
Further Information

Publication History

Received02 February 2005

Accepted after resubmission16 July 2005

Publication Date:
07 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

Coumarin and homologous compounds are the most widely used anticoagulant drugs worldwide. They function as antagonists of vitamin K, an essential cofactor for the posttranslational γ-glutamyl carboxylation of the so-called vitamin K-dependent proteins. As vitamin K hydroquinone is converted to vitamin K epoxide (VKO) in every carboxylation step, the epoxide has to be recycled to the reduced form by the vitamin K epoxide reductase complex (VKOR). Recently, a single coumarin-sensitive protein of the putativeVKOR enzyme complex was identified in humans (vitamin K epoxide reductase complex subunit 1, VKORC1). Mutations inVKORC1 result in two different phenotypes: warfarin resistance (WR) and multiple coagulation factor deficiency type 2 (VKCFD2). Here, we report on the expression of site-directed VKORC1 mutants, addressing possible structural and functional roles of all seven cysteine residues (Cys16, Cys43, Cys51, Cys85, Cys96, Cys132, Cys135), the highly conserved residue Ser/Thr57, and Arg98, known to cause VKCFD2 in humans. Our results support the hypothesis that the C132-X-X-C135 motif inVKORC1 comprises part of the redox active site that catalyzes VKO reduction and also suggest a crucial role for the hydrophobicThr-Tyr-Ala motif in coumarin binding. Furthermore, our results support the concept that different structural components of VKORC1 define the binding sites for vitamin K epoxide and coumarin.

Keywords

Vitamin K - VKOR - warfarin - CXXC motif - mutagenesis
 

  • References

  • 1 Stenflo J, Fernlund P, Egan W. et al. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 1974; 71: 2730-3.
    CrossrefPubMedGoogle Scholar
  • 2 Hauschka PV, Reid ML. Vitamin K dependence of a calcium-binding protein containing gamma-carboxyglutamic acid in chicken bone. J Biol Chem 1978; 253: 9063-8.
    CrossrefPubMedGoogle Scholar
  • 3 Price PA, Urist MR, Otawara Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem Biophys Res Commun 1983; 117: 765-71.
    CrossrefPubMedGoogle Scholar
  • 4 Goruppi S, Ruaro E, Schneider C. Gas6, the ligand of Axl tyrosine kinase receptor, has mitogenic and survival activities for serum starved NIH3T3 fibroblasts. Oncogene 1996; 12: 471-80.
    PubMedGoogle Scholar
  • 5 Locke D, Koreen IV, Hertzberg E L. et al. Isoelectric focusing and post-translational modifications of Cx26 and Cx32. Mol Biol Cell. 2004: 15S-266a.
    PubMedGoogle Scholar
  • 6 Berkner KL. The vitamin K-dependent carboxylase. J Nutr 2000; 130: 1877-80.
    CrossrefPubMedGoogle Scholar
  • 7 Mukharji I, Silverman RB. Purification of a vitamin K epoxide reductase that catalyzes conversion of vitamin K 2,3-epoxide to 3-hydroxy-2-methyl-3-phytyl-2,3-dihydronaphthoquinone. Proc Natl Acad Sci U S A 1985; 82: 2713-7.
    CrossrefPubMedGoogle Scholar
  • 8 Cain D, Hutson SM, Wallin R. Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 1997; 272: 29068-75.
    CrossrefPubMedGoogle Scholar
  • 9 Begent LA, Hill AP, Steventon G B. et al. Characterization and purification of the vitamin K1 2,3 epoxide reductases system from rat liver. J Pharm Pharmacol 2001; 53: 481-6.
    CrossrefPubMedGoogle Scholar
  • 10 Rost S, Fregin A, Ivaskevicius V. et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 2004; 427: 537-41.
    CrossrefPubMedGoogle Scholar
  • 11 Li T, Chang CY, Jin D Y. et al. Identification of the gene for vitamin K epoxide reductase. Nature 2004; 427: 541-4.
    CrossrefPubMedGoogle Scholar
  • 12 Oldenburg J, von Brederlow B, Fregin A. et al. Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex. Thromb Haemost 2000; 84: 937-41.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Tie JK, Nicchitta C, von Heijne G. et al. Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. J Biol Chem 2005; 280: 16410-6.
    CrossrefPubMedGoogle Scholar
  • 14 Goodstadt L, Ponting CP. Vitamin K epoxide reductase: homology, active site and catalytic mechanism. Trends Biochem Sci 2004; 29: 289-92.
    CrossrefPubMedGoogle Scholar
  • 15 Powis G, Montfort WR. Properties and biological activities of thioredoxins. Annu Rev Biophys Biomol Struct 2001; 30: 421-55.
    CrossrefPubMedGoogle Scholar
  • 16 Soute BA, Groenen-van Dooren MM, Holmgren A. et al. Stimulation of the dithiol-dependent reductases in the vitamin K cycle by the thioredoxin system. Strong synergistic effects with protein disulphide-isomerase. Biochem J 1992; 281: 255-9.
    CrossrefPubMedGoogle Scholar
  • 17 Thijssen HH, Janssen YP, Vervoort LT. Microsomal lipoamide reductase provides vitamin K epoxide reductase with reducing equivalents. Biochem J 1994; 297: 277-80.
    CrossrefPubMedGoogle Scholar
  • 18 Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest 1985; 76: 1879-84.
    CrossrefPubMedGoogle Scholar
  • 19 Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18: 2714-23.
    CrossrefPubMedGoogle Scholar
  • 20 Pelz HJ, Rost S, Hünerberg M. et al. The genetic basis of resistance to anticoagulants in rodents. Genetics. 2005 May 6; [Epub ahead of print].
    PubMedGoogle Scholar
  • 21 Wajih N, Sane DC, Hutson S M. et al. Engineering of a recombinant vitamin K-dependent -carboxylation system with enhanced -carboxyglutamic acid (Gla) forming capacity: Evidence for a functional CXXC RedOx center in the system. J Biol Chem 2005; 280: 10540-7.
    CrossrefPubMedGoogle Scholar
  • 22 Häse CC, Fedorova ND, Galperin M Y. et al. Sodium ion cycle in bacterial pathogens: Evidence from crossgenome comparisons. Microbiol Mol Biol Rev 2001; 65: 353-70.
    CrossrefPubMedGoogle Scholar
  • 23 Thomsen-Zieger N, Pandini V, Caprini G. et al. A singlein vivo-selected point mutation in the active center of Toxoplasma gondii ferredoxin-NADP+ reductase leads to an inactive enzyme with greatly enhanced affinity for ferredoxin. FEBS Lett 2004; 576: 375-80.
    CrossrefPubMedGoogle Scholar
  • 24 Omdahl JL, Swamy N, Serda R. et al. Affinity labeling of rat cytochrome P450C24 (CYP24) and identification of Ser57 as an active site residue. J Steroid Biochem Mol Biol 2004; 89–90: 159-62.
    CrossrefPubMedGoogle Scholar
  • 25 Hall JM, Lind C, Golvano M P. et al. Akenson A, Ehrenberg A. Structure and Function of Oxidation Reduction Enzymes.. Oxford: Pergamon Press; 1972: 433-43.
  • 26 Ma Q, Cui K, Xiao F. et al. Identification of a glycine-rich sequence as an NAD(P)H-binding site and tyrosine 128 as a dicumarol-binding site in rat liver NAD(P)H:quinone oxidoreductase by site-directed mutagenesis. J Biol Chem 1992; 267: 22298-304.
    CrossrefPubMedGoogle Scholar
  • 27 Kuijer PM, Hutten BA, Prins M H. et al. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 457-60.
    CrossrefPubMedGoogle Scholar